Iranian Journal of Neurology最新文献_第8页

Transcranial sonography in carriers of Gaucher disease. 戈谢病携带者的经颅超声检查。

Iranian Journal of Neurology Pub Date : 2018-07-06

Fatemeh Omrani, Shahla Ansari-Damavandi, Babak Zamani, Zahra Omrani, Nahid Mohammadzade, Sadra Rohani, Mohammad Rohani

{"title":"Transcranial sonography in carriers of Gaucher disease.","authors":"Fatemeh Omrani, Shahla Ansari-Damavandi, Babak Zamani, Zahra Omrani, Nahid Mohammadzade, Sadra Rohani, Mohammad Rohani","doi":"","DOIUrl":"","url":null,"abstract":"Background: Glucocerebrosidase (GBA) mutation is the most common genetic risk factor in Parkinson's disease (PD). Transcranial sonography (TCS) shows increased substantia nigra (SN) echogenicity in both idiopathic and genetic forms of PD. The goal of this study was to compare maximal area of SN hyperechogenicity (aSNmax) and diameter of third ventricle (DTV) between GBA mutation carriers and healthy controls. Methods: Twenty-six carriers of GBA mutation and twenty-six healthy controls underwent TCS. The aSNmax and the DTV were measured. Mini-mental status examination (MMSE) and demographic data of the subjects were recorded, too. Results: Mean aSNmax in GBA mutation carriers was significantly higher (0.31 ± 0.06 cm2) than controls (0.16 ± 0.04 cm2). Moreover, DTV was significantly higher in GBA mutation carriers group (3.98 ± 0.90 vs 3.29 ± 0.56 cm). Conclusion: Increased SN echogenicity and increased third ventricle diameter in GBA mutation carriers may be caused by alterations in iron metabolism with reference to their genetic status.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37231056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis 聚乙二醇化与非聚乙二醇化干扰素β 1a在复发缓解型多发性硬化症患者中的应用:成本-效果分析

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.371

Amir Hashemi-Meshkini, Hedieh-Sadat Zekri, Hasan Karimi-Yazdi, P. Zaboli, M. Sahraian, S. Nikfar

{"title":"Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis","authors":"Amir Hashemi-Meshkini, Hedieh-Sadat Zekri, Hasan Karimi-Yazdi, P. Zaboli, M. Sahraian, S. Nikfar","doi":"10.18502/IJNL.V17I3.371","DOIUrl":"https://doi.org/10.18502/IJNL.V17I3.371","url":null,"abstract":"Background: Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a compared with interferon beta 1a from an Iranian payer perspective. Methods: A Markov model was designed according to health states based on Expanded Disability Status Scale (EDSS) and one-month cycles over a 10-year time horizon. Direct medical and non-medical costs were included from a payer perspective. Results: The incremental cost-effectiveness ratio (ICER) was estimated around 11111 US dollars (USD) per quality-adjusted life-year (QALY) gained for the PEG-interferon versus interferon regimen [with currency rate of 29,000 Iranian Rial (IRR) to 1 USD in 2016]. Conclusion: Considering the cost-effectiveness threshold in Iran [three times of gross domestic product (GDP) per capita or 15,945 USD], PEG-interferon beta 1-a could be considered as a cost effective treatment for Iranian patients with MS.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42444426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Cognitive function, depression, and quality of life in patients with ruptured cerebral aneurysms. 脑动脉瘤破裂患者的认知功能、抑郁和生活质量。

Iranian Journal of Neurology Pub Date : 2018-07-06

Samira Zabyhian, Seyed Javad Mousavi-Bayegi, Humain Baharvahdat, Farhad Faridhosseini, Payam Sasannejad, Maryam Salehi, Maryam Boroumand, Zahra Hatefipour

{"title":"Cognitive function, depression, and quality of life in patients with ruptured cerebral aneurysms.","authors":"Samira Zabyhian, Seyed Javad Mousavi-Bayegi, Humain Baharvahdat, Farhad Faridhosseini, Payam Sasannejad, Maryam Salehi, Maryam Boroumand, Zahra Hatefipour","doi":"","DOIUrl":"","url":null,"abstract":"Background: Neuropsychiatric dysfunction is one of the most common complications after aneurysmal subarachnoid hemorrhage (aSAH). The aim of this study was to evaluate cognitive function, depression, and quality of life (QOL) in patients with aSAH. Methods: In this study, we prospectively enrolled patients with SAH due to rupture of anterior circulation aneurysms who referred to Ghaem hospital, Mashhad, Iran, and who had good function outcome [modified Rankin scale (mRS) > 2]. They underwent microsurgery or endovascular treatment. Cognitive function, depression, and QOL were evaluated 6 months after surgery with standard psychiatric examinations, including Mini-Mental State Examination (MMSE) for cognitive function, Hospital Anxiety and Depression Scale (HADS) for depression, and 36-Item Short Form Health Survey (SF-36) for QOL. Risk factors for cognitive dysfunction were assessed. Results: Fifty-three patients were entered the study. The mean of age was 50.9 ± 13.6 years. QOL and its components were affected in most patients. Fifty-five percent of patients suffered from depression. Cognitive impairment was found in 57% of patients. Older patients experienced more cognitive impairment (P < 0.001). Conclusion: Neuropsychological sequels are common in patients with aSAH, even if they classified as good functional outcome (mRS > 2). These complications could be found with appropriate neuropsychological evaluation of these patients to be managed as soon as possible.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis. 聚乙二醇化与非聚乙二醇化干扰素β 1a在复发缓解型多发性硬化症患者中的应用:成本-效果分析

Iranian Journal of Neurology Pub Date : 2018-07-06

Amir Hashemi-Meshkini, Hedieh Sadat Zekri, Hasan Karimi-Yazdi, Pardis Zaboli, Mohammad Ali Sahraian, Shekoufeh Nikfar

{"title":"Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.","authors":"Amir Hashemi-Meshkini, Hedieh Sadat Zekri, Hasan Karimi-Yazdi, Pardis Zaboli, Mohammad Ali Sahraian, Shekoufeh Nikfar","doi":"","DOIUrl":"","url":null,"abstract":"Background: Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a compared with interferon beta 1a from an Iranian payer perspective. Methods: A Markov model was designed according to health states based on Expanded Disability Status Scale (EDSS) and one-month cycles over a 10-year time horizon. Direct medical and non-medical costs were included from a payer perspective. Results: The incremental cost-effectiveness ratio (ICER) was estimated around 11111 US dollars (USD) per quality-adjusted life-year (QALY) gained for the PEG-interferon versus interferon regimen [with currency rate of 29,000 Iranian Rial (IRR) to 1 USD in 2016]. Conclusion: Considering the cost-effectiveness threshold in Iran [three times of gross domestic product (GDP) per capita or 15,945 USD], PEG-interferon beta 1-a could be considered as a cost effective treatment for Iranian patients with MS.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive function, depression, and quality of life in patients with ruptured cerebral aneurysms 脑动脉瘤破裂患者的认知功能、抑郁和生活质量

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.368

Samira Zabyhian, Seyed Javad Mousavi-Bayegi, H. Baharvahdat, F. Faridhosseini, P. Sasannejad, M. Salehi, M. Boroumand, Zahra Hatefipour

{"title":"Cognitive function, depression, and quality of life in patients with ruptured cerebral aneurysms","authors":"Samira Zabyhian, Seyed Javad Mousavi-Bayegi, H. Baharvahdat, F. Faridhosseini, P. Sasannejad, M. Salehi, M. Boroumand, Zahra Hatefipour","doi":"10.18502/IJNL.V17I3.368","DOIUrl":"https://doi.org/10.18502/IJNL.V17I3.368","url":null,"abstract":"Background: Neuropsychiatric dysfunction is one of the most common complications after aneurysmal subarachnoid hemorrhage (aSAH). The aim of this study was to evaluate cognitive function, depression, and quality of life (QOL) in patients with aSAH. Methods: In this study, we prospectively enrolled patients with SAH due to rupture of anterior circulation aneurysms who referred to Ghaem hospital, Mashhad, Iran, and who had good function outcome [modified Rankin scale (mRS) > 2]. They underwent microsurgery or endovascular treatment. Cognitive function, depression, and QOL were evaluated 6 months after surgery with standard psychiatric examinations, including Mini-Mental State Examination (MMSE) for cognitive function, Hospital Anxiety and Depression Scale (HADS) for depression, and 36-Item Short Form Health Survey (SF-36) for QOL. Risk factors for cognitive dysfunction were assessed. Results: Fifty-three patients were entered the study. The mean of age was 50.9 ± 13.6 years. QOL and its components were affected in most patients. Fifty-five percent of patients suffered from depression. Cognitive impairment was found in 57% of patients. Older patients experienced more cognitive impairment (P < 0.001). Conclusion: Neuropsychological sequels are common in patients with aSAH, even if they classified as good functional outcome (mRS > 2). These complications could be found with appropriate neuropsychological evaluation of these patients to be managed as soon as possible.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41277562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Validation of the Persian version of dysphagia in multiple sclerosis questionnaire for the assessment of dysphagia in multiple sclerosis 波斯版多发性硬化症吞咽困难问卷评估多发性痴呆症吞咽困难的有效性

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.365

Zahra Jafari, M. Shahbodaghi, Saman Maroufizadeh, A. Moghadasi

{"title":"Validation of the Persian version of dysphagia in multiple sclerosis questionnaire for the assessment of dysphagia in multiple sclerosis","authors":"Zahra Jafari, M. Shahbodaghi, Saman Maroufizadeh, A. Moghadasi","doi":"10.18502/IJNL.V17I3.365","DOIUrl":"https://doi.org/10.18502/IJNL.V17I3.365","url":null,"abstract":"Background: About one third of patients with multiple sclerosis (MS) experience dysphagia. Dysphagia can cause complications such as malnutrition, lung infections, aspiration pneumonia and dehydration, thus it is very helpful to diagnose dysphagia as soon as possible. The aim in this study was to translate dysphagia in multiple sclerosis (DYMUS) questionnaire into Farsi and and validate it. Methods: Forward-backward method was used to translate original English version of DYMUS into farsi, and then the questionnaire (one for each patient) was filled in through asking questions from 200 patients with MS by a speech and language pathologist. Confirmatory factor analysis (CFA) was used to examine the construct validity. Internal consistency and test-retest reliability of the DYMUS were evaluated using Cronbach’s alpha and the intraclass correlation coefficient (ICC), respectively. Results: CFA showed that a two-factor model of DYMUS including “dysphagia for solid” and “dysphagia for liquid” fitted the data well [relative chi-square [χ2/degree of freedom (df) = 1.55, CFI = 0.967, Tucker-Lewis index (TLI) = 0.957, root mean square error of approximation (RMSEA) = 0.053, and weighted root mean square residual (WRMR) = 0.874]. The Cronbach’s alpha for total score and liquid and solid subscales were 0.776, 0.557, and 0.725, respectively. The DYMUS showed adequate test-retest reliability for the total and subscales (ICC: 0.880-0.956). Moreover, this study has shown a significant relationship between DYMUS score and Expanded Disability Status Scale (EDSS) score, disease duration, type of MS, and self-reported dysphagia. Conclusion: The Persian version of DYMUS is a reliable and valid tool to screen dysphagia among patients with MS.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47391053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Oxidative stress-related biomarkers in Parkinson's disease: A systematic review and meta-analysis. 帕金森病的氧化应激相关生物标志物:系统综述和荟萃分析

Iranian Journal of Neurology Pub Date : 2018-07-06

Zeba Khan, Sharique Athar Ali

{"title":"Oxidative stress-related biomarkers in Parkinson's disease: A systematic review and meta-analysis.","authors":"Zeba Khan, Sharique Athar Ali","doi":"","DOIUrl":"","url":null,"abstract":"Parkinson's disease (PD) is a neurodegenerative disease characterized with the loss of dopamine-producing neurons in a mid-brain. This loss is believed to be associated with number of environmental and genetic factors. Oxidative stress is found to be one of the factors responsible for the initiation and progression of PD. However, studies are still continued to confirm the connection and mechanism associated with oxidative stress and PD. This systematic review and meta-analysis aimed to assess the association between oxidative stress markers and PD, and explore factors that may elucidate the contradictions in these results. As per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline systematic literature search was carried out. Meta-analysis was carried out on pooled standardized mean differences with 95% confidence interval (CI) of patients with PD and controls using random effect model in comprehensive meta-analysis statistical software. Total 17 studies were included into which 25 oxidative stress markers were analyzed. The results revealed that oxidative stress markers [nitrate and nitric oxide (NO)] and antioxidant markers [total antioxidant status (TAS) and thiols] were not statistically different between the PD and control group (P > 0.05). In case of oxidative stress markers, levels of malondialdehyde (MDA), 8-Oxo-2'-deoxyguanosine (8-oxo-dG), and lipid hydro-peroxide (LPO) were found to be high in patients with PD as compared to controls with P < 0.05, whereas lower levels of antioxidant activity of superoxide dismutase (SOD), glucose 6 phosphate dehydrogenase (G6PD), catalase (CAT), and glutathione peroxidase (GPx) were noticed in the PD group as compared to controls (P < 0.05 for all). From the results, it is concluded that patients with PD have high oxidative stress and lower antioxidant activity, and these studied biomarkers would be used as potential diagnostic tool to measure oxidative stress in patients with PD.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37231055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurobrucellosis with intramedullary spinal cord involvement: A case report 神经布鲁氏菌病伴髓内脊髓受累1例

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.376

Vida Mohammadzadeh, Samira Akbarieh, Seyed Abdolreza Ghoreishi, Manizheh Jozpanahi

引用次数: 1

The protective role of TBX21-1514T>C polymorphism in susceptibility to multiple sclerosis TBX21-1514T>C多态性在多发性硬化易感性中的保护作用

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.367

F. Akbarian, M. Ataei, Z. Salehi, M. Nabavi, M. Sanati

{"title":"The protective role of TBX21-1514T>C polymorphism in susceptibility to multiple sclerosis","authors":"F. Akbarian, M. Ataei, Z. Salehi, M. Nabavi, M. Sanati","doi":"10.18502/IJNL.V17I3.367","DOIUrl":"https://doi.org/10.18502/IJNL.V17I3.367","url":null,"abstract":"Background: As a T-cell mediated disease, multiple sclerosis (MS) pathogenesis might be associated with the immune system and its involved genes. TBX21, which encodes T-bet transcription factor, is a critical regulator of the commitment to the Th1 lineage and Interferon gamma (IFNγ) production. Investigation of the association of -1514T > C polymorphism located upstream of TBX21 gene with MS susceptibility is reasonable due to its demonstrated significant association with some other immune-mediated diseases. Methods: We analyzed the genotype frequencies of -1514T > C polymorphism between 248 Iranian patients with MS and 163 matched healthy controls. By applying polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP)- technique, the single-strand conformation patterns of the amplicons were compared and sequenced. Results: Strong association between the wild -1514T allele and MS susceptibility was found with the allelic frequency of 99.6% in patients vs. 95.1% in controls (P = 0.002), and the CC genotype frequency of the TBX21 polymorphism (-1514T > C) reported potential protective effect against the disease (P = 0.014). Conclusion: The TBX21-1514T > C polymorphism confers possible protective effect on MS in Iranian population. Further comprehensive studies in different settings are required to clarify the exact role of TBX21 gene in MS disease.","PeriodicalId":45759,"journal":{"name":"Iranian Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41504441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis 在多发性硬化症的治疗中，疾病修饰疗法诱导或加重其他免疫介导的疾病

Iranian Journal of Neurology Pub Date : 2018-07-06 DOI: 10.18502/IJNL.V17I3.372

S. Baghbanian, M. Sahraian

引用次数: 2